Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPTcycle
2024-515769-32-00Phase 3Authorised
- Sponsor
- Westdeutsche Studiengruppe
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ribociclib in breast cancer (2 arms), sponsored by Westdeutsche Studiengruppe. Primary endpoints: Invasive disease-free survival and Distant disease-free survival. Planned start Jul 2019; status: authorised.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-515769-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515769-32-00.